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ABSTRACT: Bovine brucellosis is a serious zoonotic disease affecting some populations of Rocky
Mountain elk (Cervus elaphus nelsoni) and bison (Bison bison) in the Greater Yellowstone Area,
USA. The fear that elk and/or bison may spread Brucella abortus to livestock has prompted efforts
to reduce or eliminate the disease in wildlife. Brucella abortus strain RB51 (RB51) vaccine has
recently been approved for use in cattle. Unlike strain 19 vaccine, RB51 does not cause false
positive reactions on standard brucellosis serologic tests. If effective, it may become the vaccine
of choice for wildlife. In February 1995, 45 serologically negative female elk calves were trapped
and taken to the Sybille Wildlife Research and Conservation Education Unit near Wheatland,
Wyoming, USA. In May 1995, 16 of these elk calves were hand-vaccinated with 1 ⫻ 109 colony
forming units (CFU) of RB51, 16 were vaccinated with 1 ⫻ 108 CFU RB51 by biobullet, and
13 were given a saline placebo. The elk were bred in fall of 1996 and they were challenged with
1 ⫻ 107 CFU of B. abortus strain 2308 by intraconjunctival inoculation in March 1997. Thirteen
(100%) control elk aborted, 14 (88%) hand-vaccinated elk aborted, and 12 (75%) biobullet vaccinated elk aborted or produced nonviable calves. These results suggest that a single dose of 1
⫻ 108 to 1 ⫻ 109 CFU RB51 does not provide significant protection against B. abortus induced
abortion in elk. However, the vaccine appears to be safe at this dose and additional study may
reveal a more effective RB51 vaccine regimen for elk.
Key words: Brucella abortus, brucellosis, Cervus elaphus nelsoni, Rocky Mountain elk, strain
RB51, vaccination.

Department of Agriculture Animal and
Plant Health Inspection Service (USDAAPHIS), has been quite successful. When
the program began, brucellosis affected
one in every eight cattle herds in every
state in the country (King, 1997). Today,
45 states, Puerto Rico, and the Virgin Islands are brucellosis free (United States
Department of Agriculture, 2000). The
number of human cases in the USA has
dropped from 6,321 in 1947 to about 100
per year today (Young and Nicoletti,
1997).
Bovine brucellosis causes about 70% of
female cattle to abort their first fetus following infection. Abortions typically occur
after the 5th month of infection (Nicoletti
and Gilsdorf, 1997). Most cattle will only
abort once, but 10–20% may abort in sub-

INTRODUCTION

Bovine brucellosis is an important disease of domestic and wild animals and occasionally of humans. There is much controversy about this disease in wildlife and
its impacts in the Greater Yellowstone
Area (GYA), USA and nationally. The GYA
consists of Yellowstone National Park,
Grand Teton National Park, and the surrounding areas of Montana, Wyoming, and
Idaho. This debate has implications for
management of wildlife and livestock of
the region.
The Cooperative State-Federal Brucellosis Eradication Program began in 1934
and has cost about $3.5 billion to 1997
(Frye and Hillman, 1997). This program,
which is administered by the United States
18
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sequent pregnancies. Brucellosis is transmitted by ingestion of Brucella abortus
from contaminated fetuses, placentas, and
associated fluids (Nicoletti, 1986).
Brucellosis affects elk herds that winter
on feedgrounds in western Wyoming
(Thorne et al., 1978a; 1979). The elk of
Yellowstone National Park and the National Elk Refuge in Jackson, Wyoming have
been known to be infected since the 1930s
(Rush, 1932; Thorne et al., 1978b). There
are 23 feedgrounds in western Wyoming,
where approximately 25,000 elk are fed in
the winter. Brucellosis has been documented in elk on most of these feedgrounds and is assumed to be present on
the remaining untested feedgrounds
(Thorne et al., 1991). Seroprevalence in
adult cow elk is as high as 50% on some
feedgrounds (Herriges et al., 1989). The
abortion rate among naturally exposed naive elk is about 50% for the first pregnancy
after infection, and it is estimated that
highly infected herds may lose 12% of
their reproductive potential (Thorne et al.,
1991).
Infected elk may co-mingle with cattle
on summer ranges, during migrations, and
occasionally may be in close contact with
cattle on cattle winter feedlines (Thorne et
al., 1979). Experimentally infected elk can
transmit brucellosis to susceptible cattle
when they are confined together under
conditions of prolonged close contact
(Thorne et al., 1979), although the risk in
a free-ranging situation is unknown. There
is remote potential for brucellosis transmission from elk to domestic cattle (Cheville et al.,1998). If this occurred, Wyoming could lose its status as a brucellosis
free state by the USDA-APHIS which
would be very costly to the livestock industry. Because of this threat, efforts are
being undertaken to reduce or eliminate
the prevalence of the disease in the elk
herds of northwestern Wyoming.
One method to reduce the prevalence
of the disease is through vaccination. Elk
on the state of Wyoming feedgrounds are
currently being vaccinated as calves with

19

B. abortus strain 19 (strain 19) via biobullet inoculation. Biobullets are made of a
hydroxypropylmethylcellulose shell containing 3 ⫻ 109 colony forming units
(CFU) lyophilized strain 19 and are shot
into the large muscle mass of the hind leg
(Angus, 1989; Thorne et al., 1997). To
date, about 40,000 elk have been vaccinated with strain 19 by biobullet. Although
the program is deemed successful (Cheville et al., 1998), there are some problems
with strain 19.
The biggest limitation of strain 19 is the
potential for it to induce false positive reactions on the standard brucellosis serologic tests (Stevens et al., 1994). This can
make it difficult to distinguish some vaccinated animals from those infected with
the virulent field strain of the organism.
However, a new vaccine, B. abortus
strain RB51 (RB51) does not induce false
positive reactions and is less pathogenic
than strain 19 (Schurig et al., 1991). Strain
RB51 has replaced strain 19 as the official
calfhood vaccine for cattle by USDAAPHIS (Cheville et al., 1998). If effective
in elk, RB51 would become the vaccination of choice for feedground elk as well.
There are two dose regimens for cattle: a
reduced dose for adults (109 CFU) (Olsen,
2000a) and a calfhood dose (10 10
CFU)(Olsen, 2000b). The purpose of this
study was to test the safety and efficacy of
reduced dose RB51 in preventing Brucella
induced abortion in elk vaccinated as
calves.
METHODS

In February 1995, 45 6- to 8-mo-old female
elk calves were corral trapped at the National
Elk Refuge, Teton County, Wyoming (43⬚30⬘N,
110⬚45⬘W). The calves were bled at the trap
site and screened with the card test (United
States Department of Agriculture, undated) to
insure that they were negative for Brucella antibodies. They were then shipped to the Sybille
Wildlife Research and Conservation Education
Unit, Wyoming Game and Fish Department
(41⬚45⬘N, 105⬚42⬘W), near Wheatland, Wyoming.
Over the next 8 wk, elk were bled five additional times and serologically tested for Bru-
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cella antibodies using the card test, the standard plate test, the rivanol test, and the complement fixation test (Alton et al., 1988) to be
certain that the elk had not been exposed to
Brucella. Elk were fed free choice alfalfa hay
and approximately 1 kg per head per day of
pelleted alfalfa and corn. Water and mineral
salt blocks were provided ad libitum.
Elk were randomly assigned to one of three
groups. On 9 and 10 May 1995 one group (n
⫽ 16) was vaccinated by intramuscular injection into the left hind hip with 1 ⫻ 109 CFU
of RB51 and a control group (n ⫽ 13) was similarly intramuscularly injected with a saline placebo. The final group (n ⫽ 16) was vaccinated
via biobullet with 1 ⫻ 108 CFU of RB51 on 23
May 1995. Biobullets were prepared by the Diagnostic Bacteriology Laboratory, Veterinary
Services, APHIS (Ames, Iowa, USA). Due to
complications in preparing the biobullets, the
vaccine dose of the biobullet group was a log
lower than the hand-vaccinated group, and the
biobullet group was vaccinated almost 2 wk later.
Elk were bled every 2 wk for serology and
hemoculture. In addition to the standard serologic tests mentioned above, indirect enzyme-linked immunosorbant assays (ELISAs)
for anti-RB51 antibodies prior to vaccination
and on postvaccination (PV) wk 4, 8, 10, 14,
18, and 27 were conducted (Colby, 1997). The
indirect ELISA was developed to identify elk
with B. abortus strain RB51-specific titers. Appropriate wells of 96-well, medium-binding
polystyrene plates (Costar, Kennebunk, Maine,
USA) were coated with lyophilized, acetonekilled RB51 diluted in bicarbonate phosphate
buffer (pH 9.6). Plates were sealed and incubated overnight. On the following day, plates
were washed with a phosphate buffered solution containing 0.05% Tween 20 (PBST). Serum samples were diluted in PBST, dispensed
into the antigen-coated wells, and then incubated in the RB51-coated polystyrene plates.
After incubation, the wells were washed four
times. Each well was then incubated with
mouse monoclonal anti-bovine IgG1 (Big715A,
Veterinary Medical Research and Development
Inc., Pullman, Washington, USA) diluted in
PBST. Next, the plates were washed four times
and then incubated with polyclonal horseradish
peroxidase conjugated goat IgG fraction to
mouse IgG whole molecule (Cappel, West
Chester, Pennsylvania, USA) diluted in PBST.
The plates were washed four times then incubated with a developing solution consisting of
ortho-phenylenediamine (Sigma, St. Louis,
Missouri, USA), methanol, distilled water, and
H2O2. The developing reaction in each well
was stopped with H2SO4. Optical density at 490

nm was determined for each well with a 96well plate reader (Molecular Devices Corporation, Sunnyvale, California, USA). Optical
density readings for each sample were converted into a percent positivity value for analysis.
The percent positivity of each sample represents the ratio of RB51 specific antibody in that
sample to the amount of RB51 specific antibody in the positive control. A negative cutoff
was determined above which a sample was considered to have significantly elevated anti-RB51
antibody level.
Our hemoculture protocol followed Alton et
al. (1988): 10–12 ml of blood was placed into a
sterile bottle containing soybean-casein digest
agar (Trypticase威 Soy Agar, Becton Dickinson
and Company, Cockeysville, Maryland, USA) at
a slant and 20 ml of tryptose broth (Becton
Dickinson and Company) with 1% sodium citrate. The blood was aseptically added to the
bottle incubated at 37 C with 10% CO2 atmosphere. Slants were checked for bacterial
growth twice weekly. Those with growth were
streaked on Brucella media (Kuzdas and Morse
recipe, Alton et al., 1988). Those without
growth were inverted to coat the slant with the
blood/broth mixture and returned to the incubator. Hemocultures were kept until they yielded growth or for 6 wk. Hemocultures were performed on all animals until each elk had been
negative on two consecutive samples. When
hemocultures were no longer positive, blood
samples were collected from elk monthly and
serum alone tested as above.
In late August, 1996 two mature Brucella antibody negative bull elk were introduced to
each pen for breeding. All cow elk were rectally
palpated on 30 January 1997 to confirm pregnancy. Elk were challenged by intraconjunctival
inoculation with 1 ⫻ 107 CFU B. abortus strain
2308 on 4 and 5 March 1997. This was done
by placing half the inoculating dose (in 50 l
of saline) in the bottom of each conjunctival
sac.
Elk were bled at challenge and at 2 wk intervals for hemoculture and standard serology
as described above. For the next several
months elk were closely watched from a distance for evidence of abortion or calving. Additionally, each pen was thoroughly examined
daily for fetuses or calves.
Fetuses were placed in two layers of plastic
bags and transported to the Wyoming State
Veterinary Laboratory (WSVL, Laramie, Wyoming) for necropsy to verify the cause of abortion. Abomasal contents, heart blood, cerebrospinal fluid, lungs, mandibular lymph nodes,
liver, spleen, and rectal swabs were cultured on
Brucella media (Alton et al., 1988). Brucella
plates were incubated at 37 C in 10% CO2 until
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growth was noted or for 10 days. Colonies characteristic of Brucella were identified by Gram
stain and morphology (Gram negative coccobacilli), urease (positive; United States Department of Agriculture, undated), lead acetate
(positive; Alton et al., 1988), catalase spot test
and oxidase spot test (both positive; DIFCO
Laboratories, Detroit Michigan, USA; Alton et
al., 1988). When available, cotyledons, intercotyledonary placenta, and allantoic fluid were
likewise cultured. Live calves had nasal, pharyngeal, and rectal swabs taken for Brucella
culture within a few hours of being found. Vaginal swabs were taken on all cow elk within 24
hr of delivery, again after 2–3 days, and when
elk were bled, generally about a week after delivery, and then bimonthly; swabs were cultured as above. One hand-vaccinated cow was
not identified for several days after aborting so
sampling was delayed. Vaginal swabs were taken every 2 wk until the elk had been negative
on at least two attempts.
After all elk calved or aborted, elk cows and
calves from each group were randomly euthanized and necropsied. Necropsies were performed from 15–20 wk after challenge. At necropsy the animal was examined for gross lesions
and tissues taken for Brucella culture. Tissues
cultured included the mandibular, medial and
lateral retropharyngeal, prescapular, prefemoral, popliteal, parotid, mesenteric, hepatic, external and internal iliac, bronchial, and mediastinal lymph nodes; ovaries; uterus; cervix; biceps femoris; spleen; liver; lungs; ileum; rectum; kidney; bone marrow; synovial fluid;
cerebrospinal fluid; and urine. Solid tissue samples were sliced and macerated with a scalpel
blade and rubbed over the entire surface of
Brucella media (Alton et al., 1988). Approximately 0.2 ml of cerebrospinal fluid, synovial
fluid from the antebrachiocarpal joint, and
urine were used to coat Brucella media. Brucella plates were incubated and colonies identified as stated above. Colonies on each plate
were counted and each group was assigned a
mean index of infection (Jones et al., 1964).
Briefly, an index of infection measures how
heavily infected an animal is based on the number of CFUs isolated from all tissues sampled.
Comparisons of rates of abortions between
each vaccinated group and the control group
were made via a Fisher’s exact test with P ⬍
0.10 considered significant. Comparisons of indices of infection were made via a one way
analysis of variance (ANOVA) with P ⬍ 0.10
considered significant. All statistical tests were
conducted using Number Cruncher Statistical
Systems software (NCSS䉷, 1998, Kaysville
Utah, web site: www.ncss.com). Means are reported with standard deviations (SD).

21

RESULTS

None of the hand-vaccinated elk or controls seroconverted on standard Brucella
serologic tests after vaccination. However,
all but one of the biobullet vaccinates had
short term (4–6 wk) weak positive reactions on all serologic tests (Cook, 1999).
All hand-vaccinated elk were positive on
the RB51 indirect ELISA at 4 wk PV;
three of these elk were negative, one was
suspect, and the rest were positive at 8 wk
PV; by 27 wk PV only seven were still positive. In contrast, it took 8 wk PV for all
biobullet elk to seroconvert on RB51 indirect ELISA; at 4 wk 11 were positive, six
were negative, and one was suspect. For a
complete discussion of the RB51 indirect
ELISA results see Colby, 1997. We cultured RB51 from the blood of 13 (81%) of
the biobullet inoculated animals, 10 (63%)
of the hand-vaccinated elk, and none of
the controls. Biobullet inoculated elk
cleared the vaccine strain from the blood
within 6 wk, as did most of the hand-vaccinates, but one hand-vaccinated animal
took 14 wk until cultures were negative.
No signs of disease attributable to vaccination were noted.
All control elk, 88% (14/16) of the handvaccinates, and 75% (12/16) of the biobullet vaccinates had abortions or produced nonviable calves attributable to B.
abortus strain 2308. Additionally, one
biobullet cow delivered a live calf which
died within 12 hr and from which B. abortus strain 2308 was isolated. There were
no differences in abortion rates between
controls and hand-vaccinates (P ⫽ 0.55) or
biobullet vaccinates (P ⫽ 0.15). Mean indices of infection were 8.87 ⫾ 6.80 (controls), 7.91 ⫾ 7.08 (hand), and 7.81 ⫾ 7.74
(biobullet). There were no differences in
the indices of infection (P ⫽ 0.91). Brucella abortus strain 2308 was isolated from
vaginal swabs of all control elk, 12 of 16
(75%) biobullet elk, and 14 of 15 (93%)
hand-vaccinated elk. Most elk only shed B.
abortus strain 2308 vaginally for a few days
after abortion. However, three controls
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shed for 16, 26, and 27 days post abortion;
one biobullet elk shed for 27 days, and
three hand-vaccinates shed for 15, 17, and
22 days. Brucella abortus strain 2308 was
isolated from blood of all but three elk
(two biobullet, one hand-vaccinate). Brucella abortus strain 2308 was cultured
from numerous tissues in each group (Table 1).
At necropsy, pyometras and abscesses
were found in each group. One control elk
had multiple uterine abscesses from which
Arcanobacterium pyogenes was isolated.
One hand-vaccinate had a subcutaneous
abscess on the right front leg from which
B. abortus strain 2308 was isolated. One
hand-vaccinate had pyometra containing
B. abortus strain 2308. Another hand-vaccinate had a single uterine abscess from
which Escherichia coli was isolated. A
hand-vaccinate had a sterile abscess of the
right ovary. One biobullet vaccinate had
mild sterile pyometra; another had a sterile firm abscess adjacent to the left ovary.
Brucella abortus strain 2308 was isolated from five of the six calves born live,
only one calf born to a biobullet-vaccinated elk was not infected in any of the tissues sampled. This calf’s dam was also one
of the few elk from which B. abortus was
not isolated from vaginal swabs, however,
this dam had several infected lymph nodes
at necropsy.
No Brucella was grown from swabs taken at birth from three calves from biobullet vaccinated cows. Brucella abortus
strain 2308 was cultured from nasal, pharyngeal, and rectal swabs from the other
live calf of a biobullet cow. Likewise, B.
abortus strain 2308 was cultured from the
pharyngeal swab only from one calf of a
hand-vaccinated cow and the pharyngeal
and nasal swab of the other.
All but one elk, a biobullet vaccinate,
were seropositive on standard tests by 2
wk after challenge. All elk were seropositive at 4 wk after challenge and remained
positive for the remainder of the study.

DISCUSSION

The results of this study indicate that
RB51 is safe in female elk inoculated as
calves. However, as used in this study it
may not be as effective in preventing abortion in elk as strain 19. Strain 19 is about
60% effective in preventing abortion in elk
vaccinated as calves (Thorne et al., 1981;
Herriges et al., 1989). However, in these
strain 19 studies 30% of control elk delivered live calves. Our challenge dose was
slightly higher than used in those experiments (1 ⫻ 107 CFU B. abortus strain
2308 vs. 7.5 ⫻ 106 CFU) and the dose was
split and given in both conjunctival sacs
while in the strain 19 studies it was only
placed in one conjunctival sac. Studies
with cattle have shown that reducing the
challenge dose of B. abortus strain 2308
from 5.2 ⫻ 107 CFU to 9.4 ⫻ 106 CFU
increased vaccine efficacy from 0–20% to
89–90% while only increasing live births in
control cattle from 0% to 11% (Nicoletti,
1990).
It is also known that about 18% of cattle
are naturally resistant to brucellosis and do
not abort unless given a very high dose
(Templeton and Adams, 1990). Studies on
elk indicate that 20–30% of elk are probably likewise resistant (Thorne et al.,
1978b, 1981). Based on these studies, we
would not expect 100% of our control elk
to abort unless we gave them an overwhelming dose. If we had given the elk a
challenge dose that only caused 70–80% of
controls to abort, protection of vaccinated
elk might have been higher. Calculations
of the number of bacteria harvested from
actual aborted elk fetuses indicate that
there are about 4.1 ⫻ 106 CFU on a piece
of aborted elk fetus skin 10 cm in diameter
(Cook, 1999). Observations of elk under
natural conditions indicate that most elk
simply make brief contact with a fetus and
then walk away (Cook, 1999). Most elk
probably contact an area 10 cm diameter
or less, and thus they would be exposed to
4.1 ⫻ 106 CFU or less. The dose we gave
elk was nearly a log higher than a realistic
field exposure.
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TABLE 1. Number and percent of elk from groups not vaccinated, biobullet vaccinated with RB51, and
hand-vaccinated with RB51 positive at necropsy for B. abortus strain 2308 after challenge.

Tissue

Rd mandibular LNe
Lf mandibular LN
R medial retropharyngeal LN
L medial retropharyngeal LN
R lateral retropharyngeal LN
L lateral retropharyngeal LN
R parotid LN
L parotid LN
R prescapular LN
L prescapular LN
R prefemoral LN
L prefemoral LN
R external iliac LN
L external iliac LN
R internal iliac LN
L internal iliac LN
R popliteal LN
L popliteal LN
Mediastinal LN
Mesenteric LN
Hepatic LN
Supramammary LN
Bronchial LN
Synovial fluid
Cerebrospinal fluid
Lung
Ileum
Rectum
Feces
Urine
Mammary gland L front quarter
Mammary gland L hind quarter
Mammary gland R front quarter
Mammary gland R hind quarter
Uterus
Cervix
R ovary
L ovary
Milk
R kidney
L kidney
Bone marrow
Biceps femoris
Spleen
Liver

Number positive
controlsa (%),
n ⫽ 13

5 (39)
5 (39)
9 (69)
5 (39)
3 (23)
3 (23)
3 (23)
2 (15)
4 (31)
4 (31)
1 (8)
4 (31)
6 (46)
6 (46)
3 (23)
5 (39)
3 (23)
6 (46)
3 (23)
0
2 (15)
7 (54)
2 (15)
0
0
0
0
0
0
1 (8)
5 (39)
4 (31)
1 (8)
4 (31)
3 (23)
4 (31)
0
0
2 (15)
0
0
0
0
2 (15)
1 (8)

Number positive
biobullet
vaccinatesb (%),
n ⫽ 16

6 (38)
6 (38)
10 (63)
7 (44)
2 (13)
5 (31)
5 (31)
5 (31)
3 (19)
4 (25)
7 (44)
5 (31)
4 (25)
4 (25)
4 (25)
6 (38)
4 (25)
6 (38)
2 (13)
0
3 (19)
9 (56)
2 (13)
0
0
0
0
0
0
0
4 (25)
4 (25)
4 (25)
5 (31)
5 (31)
4 (25)
1 (6)
0
2 (13)
1 (6)
0
0
0
2 (13)
2 (13)

Number positive
hand-vaccinatesc
(%), n ⫽ 16

3 (19)
4 (25)
7 (44)
6 (38)
3 (19)
5 (31)
3 (19)
5 (31)
5 (31)
3 (19)
3 (19)
2 (13)
7 (44)
3 (19)
5 (31)
4 (25)
9 (56)
2 (13)
3 (19)
2 (13)
2 (13)
8 (50)
5 (31)
0
0
0
0
0
0
0
4 (25)
2 (13)
1 (6)
3 (19)
5 (31)
7 (44)
0
1 (6)
1 (6)
1 (6)
1 (6)
0
0
2 (13)
3 (19)

Controls ⫽ pregnant elk not vaccinated but challenged with 1 ⫻ 107 CFU of B. abortus strain 2308.
Biobullet vaccinates ⫽ pregnant elk previously vaccinated with 1 ⫻ 108 CFU B. abortus strain RB51 and challenged with
1 ⫻ 107 CFU of B. abortus strain 2308.
c Hand-vaccinates ⫽ pregnant elk previously vaccinated with 1 ⫻ 109 CFU B. abortus strain RB51 and challenged with 1 ⫻
107 CFU of B. abortus strain 2308.
d R ⫽ right.
e LN ⫽ lymph node.
f L ⫽ left.
a

b
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In a previous study, pregnant elk were
orally vaccinated with 2 ⫻ 1010 CFU RB51
and challenged about 2 mo later. In this
study, four of nine oral RB51 vaccinates
produced live calves while none of 15 controls produced live calves; RB51 was considered to be partially protective (Elzer
and Davis, 1997). When animals are exposed to B. abortus the bacteria generally
invade through the mucosa (Enright,
1990). It may be that mucosal immunity is
important in determining protection
against B. abortus. Oral vaccination may
better stimulate mucosal immunity and
may therefore be more effective than intramuscular vaccination. In the present
study elk were challenged nearly 2 yr PV
while in the above study it was 2 mo after
vaccination. Perhaps vaccine induced immunity had waned over the extended period.
Results of the indices of infection were
very similar from each group. There was
little difference in the percent of animals
from each group which were infected in
each tissue (Table 1). Additionally, there
was little difference in hemoculture results. This, combined with the abortion
rates of each group, indicates that the vaccine provided little protection. It may be
that a higher dose of RB51 would have
stimulated greater resistance. However,
one elk died 27 days after vaccination and
tissues were cultured for RB51 (Cook,
1999). The vaccine strain was cultured
from many lymph nodes and a few other
tissues. Thus, the vaccine dose was sufficiently high for the vaccine strain to colonize multiple sites. It seems unlikely that
a higher dose would stimulate greater immunity.
We also identified tissues most likely to
be infected when elk are intraconjunctivally infected with B. abortus strain 2308
(Table 1). Lymph nodes of the head and
the iliac and supramammary lymph nodes
as well as the uterus, cervix, and mammary
glands are the tissues most likely to be infected. Results of vaginal swab cultures indicate that a few elk shed B. abortus strain

2308 vaginally for extended periods of
time. Seven elk shed the bacteria for a
minimum of 15 days. It is likely that several elk shed the bacteria longer than was
documented because elk were only sampled every 2 wk. It is not known if these
elk were shedding adequate amounts of
bacteria to infect other elk because the
number of bacteria was not quantified.
It is unknown why most of the biobullet
vaccinates developed short term weak positive reactions on the standard brucellosis
serologic tests. One possibility is that the
biobullets were contaminated with strain
19. Unused biobullets from the same
batch were cultured and revealed only
pure strain RB51. Additionally, all hemoculture B. abortus isolates recovered PV
were 100% RB51 with no reversions to the
smooth bacterial phenotype (Colby, 1997).
It is possible that in the process of firing
biobullets into the muscles other bacteria
which might cause seroconversion entered
into the wound. Yersinia enterocolitica,
Salmonella urbana, E. coli O:116, and
Pseudomonas maltophilia may induce reactions on standard brucellosis serology
(MacMillan, 1990). However, it seems unlikely that 17 of 18 biobullet elk would
have become infected with one of these
bacteria. It is also possible that the process
of firing the biobullet changed the characteristics of RB51 in some way. Again this
seems unlikely because, as stated above,
hemoculture isolates did not show any reversion to smooth characteristics.
Regardless of the cause of the short
term serologic reactions of the biobullet
vaccinated group it would not be a concern if the vaccine were used in a field
situation. If it were used in biobullet form,
the vaccine would be administered in late
winter. Serologic testing of elk occurs at
two times. First, hunter harvested elk are
tested; second, elk are trapped and tested
on feedgrounds prior to vaccination. In
both cases elk would be vaccinated 6 to 12
mo prior to being tested, well beyond the
time antibody titers induced by vaccination would no longer be detected.
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In cattle, RB51 offers protection similar
to strain 19 (Cheville et al., 1993, 1996).
Thus, it may still be possible that a vaccination program using RB51 could be developed for elk. Elk may require a higher
vaccine dose than we used, the oral route
maybe more effective than parenteral inoculation, the challenge dose used here
may have been unrealistically high, or perhaps elk require a booster dose of RB51
in order to develop adequate protection.
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